December 10, 2016
Steven C. Eror , President and CEO of ProLung, meets with Gregory C. Simon , White House Cancer Moonshot Task Force, Executive Director in the Office of the Vice President.
November 02, 2016
ProLungDX seeks funds for cancer test; sees eventual IPO – CEO Proprietary Intelligence ProLungDX , a maker of lung cancer detection devices, is looking to raise USD 5.25m from high net worth investors for US commercial development in advance of an expected initial public offering or trade sale,
October 13, 2016
Salt Lake City, UT, USA, October 13, 2016 – ProLungdx™ today announced plans to present its leading-edge innovation for patients at risk of lung cancer during the 2016 BIO Investor Forum in San Francisco, California October 18 and 19, 2016. For the first time in an international biotech
September 07, 2016
Salt Lake City, UT, USA, September 7, 2016 – ProLungdx™ today announced plans to present its ground-breaking innovation for lung cancer patients at the AZBIO’s 2016 White Hat Life Science Investors Conference in Phoenix, Arizona September 21 and 22, 2016.
June 04, 2016
Lung cancer survival rate increases by 73% if caught early. A major lung cancer screening trial, conducted by experts at the University of Liverpool, has found that patients with a high risk of developing lung cancer can be identified with early stage disease and have up to a 73% chance
May 26, 2016
Salt Lake City, Utah, May 25, 2016 – The Board of Directors of Fresh Medical Laboratories Inc., doing business as ProLungdx, today announced the appointment of Dr. John C. Ruckdeschel, M.D. to serve as a Director on the Company’s Board of Directors. Dr.
May 19, 2016
Salt Lake City, Utah, May 19, 2016 – Fresh Medical Laboratories, Inc, doing business as ProLungdx™, announced today that its board has appointed Todd Morgan as Chairman of the Board of Directors. Mr. Morgan succeeds Clark Campbell, who served as the Chairman from 2012 to 2016.
May 18, 2016
ProLungdx EPN Scan® Confirms Performance in Early Lung Cancer Risk Salt Lake City, Utah, USA, May 18, 2016 – Fresh Medical Laboratories, Inc., doing business as ProLungdx™, today announced the initial results of its ongoing European Lung Cancer Registry.